Pacific Biosciences Q4 Revenues Jump 43 Percent

Feb 06, 2020

|

NEW YORK – Pacific Biosciences reported after the close of the market Thursday that its fourth quarter 2019 revenues rose 43 percent.

The long-read sequencing technologies firm reported Q4 total revenues of $27.9 million, up from $19.5 million in Q4 of 2018 and beating analysts' average estimate of $25.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Featured White Papers

Single-cell Sequencing 101: DNA & multi-omics for precision medicine

B Cell Isolation for Single Cell Genomics

Nucleic Acid Contamination Application Ebook

Prevalence of Hereditary Cancer and Benefits of Multi-Gene Panel Testing

Mar

09

Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams.

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Menu

Pacific Biosciences Q4 Revenues Jump 43 Percent

To read the full story....

Breaking News

People in the News: New Appointments at Qiagen, ImmunoScape, 908 Devices, More

New Products Posted to GenomeWeb: Twist Bioscience, New England Biolabs, Promega, More

In Brief This Week: Thermo Fisher Scientific, Fourth Circuit Court of Appeals, Invitae, and More

GenDx HLA Genotyping Products Receives Health Canada IVD Approval

Personalis Q4 Revenues up 11 Percent

Natera Revenues Grow 35 Percent in Q4

The Scan

Even Bigger

Got Into the Lab Machines

Not Going to Pay

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

Featured White Papers

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

What's Popular?

Personalis to Broaden Liquid Biopsy Footprint With Minimal Residual Disease Testing

Adaptive Biotechnologies Touts New Era of T Cell-Based Dx With T-Detect COVID Launch

New Method Provides NGS-Based Readout of Glycan Levels in Single Cells

Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

Haplotype-Resolved Human Genomes Help Complete Picture of Structural Variants

Sponsorships